Workstream Type: Informing Dialogue

  • The Drugs at the Heart of Our Pricing Crisis

  • Biosimilars: Market Changes do not equal policy success

  • Curbing Biologic Drug Spending with P-quad

  • Ethics of Clinical Trials to Evaluate Biosimilars

  • COVID-19 Reduced Average Life Expectancy of Americans by Five Days, Not One Year

  • Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students

  • Research on the current state of US drug pricing and its effects

  • Who Is Sowing Seeds of Confusion About The QALY?

  • Before Spending Billions, U.S. Hospitals Need to Study Remdesivir Further

  • COVID-19 Urgency for a Vaccine Demands Patience